ARTICLE
|
doi:10.20944/preprints202105.0546.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
triple negative breast cancer; Pembrolizumab; Atezolizumab; chemotherapy; anti-PD-L1; biomarkers; targeted therapies; development of novel drugs
Online: 24 May 2021 (09:23:50 CEST)